Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Showcases High Quality Diagnostic Reagents and System Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its comprehensive portfolio of clinical chemistry analyzers, reagents, calibrators and controls at MEDICA 2023. More...

DiaSys offers complete system solutions including analyzer, reagents, and software. At MEDICA 2023, DiaSys is highlighting the respons910 benchtop analyzer which has a throughput of 100 to 150 tests/hour and is ideal for laboratories with a test volume of up to 500 tests per shift. Its high onboard capacity of 30 different methods in mono- or twin-containers and 30 sample positions offers the necessary flexibility for everyday use. Alongside the respons910, DiaSys is showcasing the respons920 benchtop analyzer with higher speed and guaranteed throughput of 200 tests/h and 360 tests/hour with ISE. With an on-board capacity of 30 different methods in mono- or twin containers, 30 samples plus nine positions for calibrators, controls, or emergency samples, respons920 offers almost unlimited flexibility in organizing laboratory workflows.

DiaSys is also highlighting the respons940 automated random access clinical chemistry analyzer that offers a constant throughput of a minimum of 400 tests/h, independent of whether a mono- or two-component reagent is used. Together with modern software features, pre-programmed applications, and carry-over evasion lists, respons940 analyzer delivers high-quality results for a broad parameter portfolio. Among the company’s products being highlighted at the show is the DiaSys CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls that allow true differentiation of borderline cases. DiaSys has extended its cardiovascular risk assessment portfolio with two innovative new reagents, HDL-c direct FS and LDL-c direct FS. Both are homogenous assays for direct determination. DiaSys has also expanded the application range for its Total bile acids 21 FS reagent and now offers the assay for use in serum and stool samples.

Related Links:
DiaSys Diagnostic Systems


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.